China Insulin Glargine Market Research Report 2021-2025 – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “China Insulin Glargine Market Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

According to the market research, the sales value of insulin glargine showed an upward trend from 2016 to 2020 in China, reaching CNY 960.49 million in 2020. Sales growth in 2020 slowed down compared to years previous ones.

The main reason is that the COVID-19 outbreak has impacted the hospital’s overall diagnosis and treatment business. The sales value CAGR of insulin glargine in the Chinese market is 5.45% from 2016 to 2020.

Insulin glargine is a long-acting human insulin analogue that can control the patient’s blood sugar more effectively and steadily. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi and its trade name is Lantus, which entered the Chinese market in 2004. In 2020, in addition to the company of original research, other manufacturers in China insulin glargine market are Gan&Lee Pharmaceuticals Co., Ltd. and Zhuhai United Laboratories Co., Ltd.

The analyst predicts that from 2021 to 2025, Insulin Glargine sales in China will experience recovery growth as the epidemic improves and the hospital’s overall diagnostic and treatment business operates normally. Moreover, its sales will also increase due to the expansion of the market.

The number of diabetes patients in China is the first in the world, and there is a great demand for drugs for the treatment of diabetes. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance and duration of action, indicating that the insulin glargine market has room for growth in China.

Besides, the key insulin glargine patent expired in 2015 and more generic drugs will appear in the insulin glargine market in the future. Therefore, the price of insulin glargine is expected to continue to decline, leading to an increase in sales volume.

Topics Covered:

  • The impact of COVID-19 on the Chinese insulin glargine market

  • Insulin glargine sales value in China 2016-2020

  • Competitive landscape of China insulin glargine market

  • Insulin glargine price in china

  • Insulin Glargine Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese insulin glargine market

  • China insulin glargine market outlook from 2021 to 2025

Main topics covered:

1 Relevant concepts of insulin glargine

1.1 Indications for insulin glargine

1.2 Insulin Glargine Development in China

1.3 Government approval of insulin glargine in China

1.4 The impact of COVID-19 on insulin glargine sales in China

2 China Insulin Glargine Sales, 2016-2020

2.1 Insulin Glargine Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Insulin Glargine Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Insulin Glargine Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Insulin Glargine Key Manufacturers in China, 2016-2020

3.1 Insulin Glargine Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Sanofi-Aventis Deutschland GmbH Germany

3.2.1 Company profile

3.2.2 LANTUS & TOUJEO (Insulin Glargine by Sanofi-Aventis Deutschland GmbH Germany) Sales in China

3.3 Gan&Lee Pharmaceuticals Co., Ltd.

3.3.1 Company Profile

3.3.2 BASALIN (Gan&Lee Pharmaceuticals Co., Ltd.’s insulin glargine) Sales in China

3.4 Zhuhai United Laboratories Co., Ltd.

3.4.1 Company Profile

3.4.2 USLEN (Insulin Glargine by Zhuhai United Laboratories Co., Ltd.) Sales in China

4 Insulin Glargine Price for Different Manufacturers in China, 2020-2021

4.1 Sanofi-Aventis Deutschland GmbH Germany (LANTUS & TOUJEO)

4.2 Gan&Lee Pharmaceuticals Co., Ltd. (BASALINE)

4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)

5 China Insulin Glargine Market Outlook, 2021-2025

5.1 Influencing Factors of China Insulin Glargine Market Development

5.1.1 The impact of COVID-19 on the Chinese insulin glargine market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/rgchit

Share.

Comments are closed.